270 results
6-K
EX-99.1
MESO
Mesoblast Ltd
3 Oct 19
Current report (foreign)
6:03am
Exhibit 99.1
September 2019
Chronic Low Back Pain Associated With Degenerative Disc Disease – A Major Unmet Medical Need
Grünenthal, a global … cell therapy candidate for the treatment of chronic low back pain associated with degenerative disc disease in patients who have exhausted
6-K
EX-99.1
MESO
Mesoblast Ltd
1 Jul 21
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
9:10pm
Exhibit 99.1
MESOBLAST PROVIDES UPDATE ON PROGRAM FOR CHRONIC LOW BACK PAIN DUE TO DEGENERATIVE DISC DISEASE
Melbourne, Australia; July 1, and New … provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due
6-K
EX-99.3
MESO
Mesoblast Ltd
19 Jan 21
Current report (foreign)
6:02am
Localized inflammatory diseases Advanced Heart Failure Chronic Low Back Pain End-Stage Ischemic Heart Failure PRODUCT CANDIDATE THERAPEUTIC AREA PHASE 1/2 … voting closed
MPC-06-ID for Chronic Low Back Pain Phase 3 trial of MPC-06-ID for chronic low back pain in 404 patients: Final study visits for all
6-K
EX-99.1
MESO
Mesoblast Ltd
19 Aug 19
Remestemcel-l to Be Evaluated As Treatment for Chronic Graft Versus Host Disease In Planned Investigator-initiated Trial
6:04am
Exhibit 99.1
REMESTEMCEL-L TO BE EVALUATED AS TREATMENT FOR CHRONIC GRAFT VERSUS HOST DISEASE IN PLANNED INVESTIGATOR-INITIATED TRIAL
Melbourne … an investigator-initiated Investigational New Drug (IND) submission as a potential treatment in children with steroid-refractory chronic graft-versus-host
6-K
EX-99.1
MESO
Mesoblast Ltd
26 Feb 20
Current report (foreign)
12:00am
Exhibit 99.1
CLINICALLY MEANINGFUL OUTCOMES USING REMESTEMCEL-L
IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE
Melbourne, Australia, February … remestemcel-L for steroid-refractory chronic graft versus host disease (chronic GVHD) has resulted in clinically meaningful outcomes in all three treated
6-K
EX-99.2
5f7b1ys bc
11 Sep 19
Current report (foreign)
6:35am
6-K
EX-99.1
otumfgi n9zio
11 Sep 19
Current report (foreign)
6:35am
6-K
EX-99.3
54jzgtrrd5ahiyw2kvjc
28 Nov 22
Current report (foreign)
6:13am
6-K
EX-99.1
l1kmpigtclv6 1a5g
17 Dec 21
Fda’s Otat In Agreement with 12-MONTH Reduction In Pain As Primary Endpoint for Chronic Low Back Pain Program
12:00am
6-K
EX-99.1
6im3yosyc dny
1 Apr 21
Mesoblast Operational Highlights and Upcoming Milestones
12:00am
6-K
EX-99.1
vp6ap
11 Feb 21
Current report (foreign)
6:04am
6-K
EX-99.2
9mxrwqu8ttukcn
31 Aug 22
Current report (foreign)
6:36am
6-K
EX-99.1
7sxwngeadaa20kncwa
19 Jan 21
Current report (foreign)
6:02am
6-K
EX-99.2
966yo1ks7w
22 Feb 19
Current report (foreign)
12:00am
6-K
EX-99.2
5rpf75 fwo1
1 Sep 21
Current report (foreign)
12:00am
6-K
EX-99.2
t3cf3uc
29 Nov 19
Current report (foreign)
6:47am
6-K
EX-99.1
tq60u9t8rr06
4 Jun 21
Current report (foreign)
6:00am
6-K
EX-99.3
ijdi azvqarg4jxm
3 Jun 22
Current report (foreign)
9:26am
6-K
EX-99.1
ski tfxpab1t1dkqb6
7 Oct 21
Rexlemestrocel-l Phase 3 Trial Results In Chronic Heart Failure Selected As Late Breaking Presentation at American Heart Association Annual Meeting
9:36pm
6-K
EX-99.2
qcp61j9x20
27 Nov 19
Continued Increase in Revenues and Strong Balance Sheet
6:04am